Abstract
The NCI imbedded the notion of comprehensive quality control and assurance (CQA) in the design concept for the Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial. PLCO implemented a comprehensive, adaptable quality assurance and control program to span more than 20 years of data collection, coordinate multiple institutions and committees, and integrate a wide variety of complex protocols. CQA concepts, practices, and procedures traced through all aspects of trial management, governance, and operations of PLCO. The driving force behind CQA in PLCO was scientific and clinical credibility of trial data and findings. CQA as implemented in PLCO was operationally analogous to the concept of Total Quality Management (TQM) described in the management literature. This paper describes CQA actualization in PLCO.
Keywords: Cancer screening, clinical trial, comprehensive quality assurance, total quality management.
Reviews on Recent Clinical Trials
Title:Comprehensive Quality Management (CQM) in the PLCO Trial
Volume: 10 Issue: 3
Author(s): John K. Gohagan, Barbara O’Brien, Marsha A. Hasson, Keith D. Umbel, Beth Bridgeman, Barnett S. Kramer, Douglas Reding, Lisa Gren, Patrick Wright, Thomas Riley and Philip C. Prorok
Affiliation:
Keywords: Cancer screening, clinical trial, comprehensive quality assurance, total quality management.
Abstract: The NCI imbedded the notion of comprehensive quality control and assurance (CQA) in the design concept for the Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial. PLCO implemented a comprehensive, adaptable quality assurance and control program to span more than 20 years of data collection, coordinate multiple institutions and committees, and integrate a wide variety of complex protocols. CQA concepts, practices, and procedures traced through all aspects of trial management, governance, and operations of PLCO. The driving force behind CQA in PLCO was scientific and clinical credibility of trial data and findings. CQA as implemented in PLCO was operationally analogous to the concept of Total Quality Management (TQM) described in the management literature. This paper describes CQA actualization in PLCO.
Export Options
About this article
Cite this article as:
K. Gohagan John, O’Brien Barbara, A. Hasson Marsha, D. Umbel Keith, Bridgeman Beth, S. Kramer Barnett, Reding Douglas, Gren Lisa, Wright Patrick, Riley Thomas and C. Prorok Philip, Comprehensive Quality Management (CQM) in the PLCO Trial, Reviews on Recent Clinical Trials 2015; 10 (3) . https://dx.doi.org/10.2174/1574887110666150730121113
DOI https://dx.doi.org/10.2174/1574887110666150730121113 |
Print ISSN 1574-8871 |
Publisher Name Bentham Science Publisher |
Online ISSN 1876-1038 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Functionalized Nanocarriers for Enhanced Bioactive Delivery to Squamous Cell Carcinomas: Targeting Approaches and Related Biopharmaceutical Aspects
Current Pharmaceutical Design Medullary Thyroid Cancer: A Promising Model for Targeted Therapy
Current Molecular Medicine Meet the Editorial Board:
Current Drug Targets Anti-Gene Strategies to Down-Regulate Gene Expression in Mammalian Cells
Current Pharmaceutical Design Triggering PIK3CA Mutations in PI3K/Akt/mTOR Axis: Exploration of Newer Inhibitors and Rational Preventive Strategies
Current Pharmaceutical Design Frequency of Pathological Types of Hyperthyroidism in Thyroid Scan Patients
Current Medical Imaging Recent Advances in Herbal Nanomedicines for Cancer Treatment
Current Molecular Pharmacology Alternative Spliced Variants as Biomarkers of Colorectal Cancer
Current Drug Metabolism New and Highly Potent Antitumor Natural Products from Marine-Derived Fungi: Covering the Period from 2003 to 2012
Current Topics in Medicinal Chemistry Therapeutic Agents Based on DNA Sequence Specific Binding
Current Topics in Medicinal Chemistry Serenoa Repens, Lycopene and Selenium: A Triple Therapeutic Approach to Manage Benign Prostatic Hyperplasia
Current Medicinal Chemistry Curcumin and its Multi-target Function Against Pain and Inflammation: An Update of Pre-clinical Data
Current Drug Targets Preface
Current Radiopharmaceuticals Cruciferous Vegetables as Antioxidative, Chemopreventive and Antineoplasic Functional Foods: Preclinical and Clinical Evidences of Sulforaphane Against Prostate Cancers
Current Pharmaceutical Design Targeting Bcl-2 Family of Proteins: An Important Strategy in Cancer Therapeutics
Current Chemical Biology PET Imaging to Monitor Cancer Therapy
Current Pharmaceutical Biotechnology The Role of YY1 in Oncogenesis and Its Potential as a Drug Target in Cancer Therapies
Current Cancer Drug Targets A Pilot Study on Prostate Cancer Risk and Pro-Inflammatory Genotypes: Pathophysiology and Therapeutic Implications
Current Pharmaceutical Design Synthesis and Cytotoxicity of Two Active Metabolites of Larotaxel
Anti-Cancer Agents in Medicinal Chemistry Mesothelioma - Update on Management
Current Respiratory Medicine Reviews